The National Comprehensive Cancer Network (NCCN) Oncology Research Program has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib in solid tumors, including breast, head and neck, and non-small cell lung cancers.
The first phase of the program will involve the establishment of an NCCN Afatinib request for proposals development team to evaluate existing data and also discuss and define the data and type of studies necessary to further characterize the clinical effectiveness of Afatinib in selected solid tumors.
Afatinib is an oral, once-daily, targeted investigational compound currently being investigated for various tumor types. It is a next-generation tyrosine kinase inhibitor, which is an irreversible inhibitor of the epidermal growth factor receptor and the human epidermal growth factor receptor 2. Afatinib is currently in phase III clinical development for non-small cell lung and breast cancers.
